Kisspeptin-10 sits one step above the hormones most people have heard of, and that position is the whole reason it is studied. It is the ten-residue active fragment of a larger peptide that signals to the neurons which release gonadotropin-releasing hormone — the top of the reproductive endocrine cascade. Nothing downstream fires without it. A molecule that gates a cascade from above is a different kind of research tool from one that acts at the bottom, and the difference shows in how experiments with it have to be designed.
What it is
The KISS1 gene encodes a precursor that is cleaved into kisspeptin-54, and shorter fragments — 14, 13 and 10 residues — that share the C-terminal end. All of them bind the same receptor, KISS1R (formerly GPR54), with comparable affinity, because the receptor recognises the C-terminal ten. Kisspeptin-10 is therefore the minimal active fragment, amidated at the C-terminus as the native forms are, and it is the one most often used in research for the same reason sermorelin is: it is the smallest thing that does the full job at the receptor.
The gene's name is a footnote worth knowing. It was first identified as a metastasis suppressor and named after Hershey, Pennsylvania's best-known export, with the "SS" for suppressor sequence. Its reproductive role was discovered years later, when mutations in the receptor were found to cause failure of puberty. The name has nothing to do with what it does.
What does the receptor do when it is activated?
KISS1R is a class A G-protein-coupled receptor coupling principally through Gαq, so activation raises intracellular calcium rather than cAMP — a different readout from the class B receptors that dominate this catalogue. On GnRH neurons, that calcium signal drives depolarisation and GnRH release, which in turn drives the pituitary to release the gonadotropins. The signal is therefore three steps removed from the hormones usually measured, and every step adds a delay and a feedback loop.
Why is the position in the cascade a design problem?
Because the system is built to resist being pushed. GnRH is released in pulses, and the pituitary responds to pulse frequency rather than to steady concentration — a continuous GnRH signal desensitises the receptor and shuts the axis down, which is the basis of an entire class of clinical agents. Kisspeptin acts one step above that, so sustained kisspeptin exposure risks the same desensitisation by proxy. An experiment applying it continuously and one applying it in pulses are asking opposite questions, and the literature contains both without always saying which.
Reading the compound
| Property | Kisspeptin-10 |
|---|---|
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Receptor | KISS1R, Gαq-coupled |
| Readout | Intracellular calcium; downstream GnRH |
| Half-life | Minutes; degraded by matrix metalloproteinases and neprilysin |
| Weak residues | Two Asn, one Trp |
The last row follows from the sequence. Two asparagines are two deamidation sites, and the Asn-Ser and Asn-Trp contexts are moderately fast; a tryptophan is a photo-oxidation site. Reading those from the letters is what tells you this is a solution to make fresh and keep dark rather than one to store.
Why is the half-life so short, and does it matter in vitro?
It is a native, unmodified fragment with no capping and no substitutions, so proteases take it apart within minutes in any system that contains them. None of the usual extension strategies has been applied, because the research value lies in it being the native ligand. In a cell-based assay the consequence is practical: serum-containing medium and many cell lines carry neprilysin activity, so the concentration added is not the concentration present ten minutes later. A calcium readout, which is fast, largely sidesteps this; a readout hours later does not.
Is kisspeptin-10 the same as kisspeptin-54?
At the receptor, close enough; in a system, no. The two bind KISS1R with similar affinity, so a binding or calcium assay will barely distinguish them. But kisspeptin-54 is cleared more slowly, distributes differently, and in whole-organism work produces a longer signal. A paper using one does not describe the other for anything time-dependent, which is the recurring problem with fragments and their parents in a slightly different form: here the fragment is the sharper tool, not the weaker one.
What should an experiment with it control for?
Three things specifically. Whether the system expresses KISS1R at all — many cell lines do not, and a null result on a receptor-negative line says nothing. Whether the medium contains proteases that will remove the peptide during the assay. And whether exposure is pulsed or continuous, since the two produce different and sometimes opposite results. Beyond those, the ordinary rules: a lot certificate, a vehicle control, and a concentration range wide enough to see a curve rather than a point — the compound is inexpensive enough that the range is not where to economise.
Why is kisspeptin-10 amidated?
Because the receptor requires it. All the native kisspeptins share an amidated C-terminal phenylalanine, and that amide is part of what KISS1R recognises: the free-acid form, with a carboxyl at that position, is close to inactive. This is a general pattern among peptide hormones that signal through class A receptors — the amide removes a negative charge and presents the terminus in the geometry the binding pocket expects. Practically, it means a preparation described only as "kisspeptin-10" without the amide is a different and largely inert molecule, and the identity panel on the certificate is where that gets confirmed: the amidated form sits one mass unit below the free acid.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
